Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Group To Press India Compulsory Licensing For Score Of Cancer Drugs

This article was originally published in PharmAsia News

Executive Summary

An Indian patient advocacy group says it plans to draw on support from other health care groups and seek a compulsory license for 20 cancer drugs. Most of the targeted drugs are made by major international drug makers. Cancer Patients Aids Association says it will try to convince the health ministry to invoke the compulsory licenses and is ready to take the matter to the Supreme Court. CPAA President Y. K. Sapru said it makes no sense to fight patent cases against individual drugs. A challenge to the Novartis patent for its leukemia drug Gleevec (imatinib mesylate) failed last year. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068075

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel